Stephane Wong
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia research, Chronic Lymphocytic Leukemia Research, CAR-T cell therapy research, RNA Interference and Gene Delivery
Most-Cited Works
- → The BCR-ABL Story: Bench to Bedside and Back(2004)402 cited
- → Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase(2018)129 cited
- → Phosphoinositide 3-kinase signaling is essential for ABL oncogene–mediated transformation of B-lineage cells(2004)85 cited
- → Regulation of the Oncogenic Activity of BCR-ABL by a Tightly Bound Substrate Protein RIN1(1997)84 cited
- → Modeling Philadelphia chromosome positive leukemias(2001)74 cited
- → Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene(2002)56 cited
- → A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial(2012)56 cited
- → Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system(2012)50 cited
- → Initial Findings From the PACE Trial: A Pivotal Phase 2 Study of Ponatinib in Patients with CML and Ph+ ALL Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I Mutation(2011)48 cited
- → The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia(2011)47 cited